Journal
BRITISH JOURNAL OF CANCER
Volume 124, Issue 4, Pages 681-682Publisher
SPRINGERNATURE
DOI: 10.1038/s41416-020-01183-y
Keywords
-
Categories
Funding
- Japan Society for the Promotion of Science [19K09840]
- START-program Japan Science and Technology Agency (JST) [STSC20001]
- National Hospital Organization Multicenter [2019-Cancer in general-02]
- Grants-in-Aid for Scientific Research [19K09840] Funding Source: KAKEN
Ask authors/readers for more resources
Drug-resistant tumors pose a significant challenge in cancer treatment, with epigenetic changes being reported as one mechanism of resistance. Clinically, combination therapy utilizing epigenetic-related drugs may be a potential future approach for cancer treatment.
During treatment, the development of drug-resistant tumours remains an important challenge in cancer treatment. Epigenetic changes have been reported as one of the mechanisms for anti-tumour drug resistance. In clinical practice, a combination of epigenetic-related drugs can be considered as a future selection of cancer therapeutic drugs.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
